RxDoctor Payments Data

Mohammad Ashraf, MD

Internal Medicine · Madera, CANPI 1881616159

Payments from drug & device makers

$3,659in general payments, 2019–2025

Across 153 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$708
  • Merck$338
  • Dilon Technologies, Inc.$310
  • AstraZeneca$298
  • Amgen$236
  • Lilly USA, LLC$183
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,57498%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,659 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$442,921
Medicare patients
489
Services billed
4,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan304$257,063
EliquisApixaban237$175,849
JardianceEmpagliflozin158$138,931
XareltoRivaroxaban102$87,662
OzempicSemaglutide36$40,832
JanuviaSitagliptin Phosphate36$29,644
FarxigaDapagliflozin Propanediol46$24,824
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,095
BrilintaTicagrelor27$14,747
CorlanorIvabradine Hcl12$13,561
TradjentaLinagliptin16$13,157
MounjaroTirzepatide11$11,331
KerendiaFinerenone12$11,264
Glucagon Emergency KitGlucagon11$9,844
Metoprolol Succinate550$8,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$113$257,063304 claims
PfizerEliquis$149$175,849237 claims
Boehringer IngelheimJardiance, Tradjenta$64$152,088174 claims
Johnson & JohnsonXarelto$111$87,662102 claims
Novo NordiskOzempic$162$40,83236 claims
AstraZenecaFarxiga, Brilinta$298$39,57173 claims
MerckJanuvia$338$29,64436 claims
AmgenCorlanor$236$13,56112 claims
Lilly USA, LLCMounjaro$183$11,33111 claims
BayerKerendia$708$11,26412 claims
Arbor Pharmaceuticals, Inc.Edarbi$33$6,66120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →